RxDoctor Payments Data

Antonio Navarrete-Casas, MD

Cardiovascular Disease · Muncie, INNPI 1265400683

Payments from drug & device makers

$38,704in general payments, 2019–2025

Across 147 payments — averaging $263.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medical Device Business Services, Inc.$27K
  • Abbott$5K
  • Boston Scientific$3K
  • Biosense Webster, Inc.$3K
  • Medtronic$297
  • Elutia, Inc.$263
  • plus $384 from 8 others

What the payments were for

  • Consulting fees$28,96075%
  • Travel & lodging$5,66115%
  • Food & beverage$4,06310%
  • Education$200%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$38,704 in reported general payments places this provider in the 80th percentile of 408 cardiovascular disease providers in Indiana.

See all cardiovascular disease providers in Indiana

Medicare billing

Part B allowed, 2024
$219,869
Medicare patients
852
Services billed
1,717

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban342$377,523
XareltoRivaroxaban64$78,264
MultaqDronedarone Hcl24$36,026
EntrestoSacubitril/Valsartan27$30,504
Flecainide Acetate217$11,528
FarxigaDapagliflozin Propanediol15$11,336
CorlanorIvabradine Hcl11$8,796
Dabigatran EtexilateDabigatran Etexilate Mesylate14$3,982
Diltiazem 24hr Er (Cd)Diltiazem Hcl105$3,140
Metoprolol Succinate203$3,117
Amiodarone Hcl64$1,822
Mexiletine Hcl13$1,507
SotalolSotalol Hcl26$643
Valsartan15$640
Propafenone Hcl12$622

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$64$377,523342 claims
AstraZenecaFarxiga$19$11,33615 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 408 cardiovascular disease providers in Indiana.

Other cardiovascular disease in Muncie

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →